Crosslinker, crosslinking system for posterior sclera treatment

Abstract

The present invention provides a cross-linking device and a cross-linking system for sclera treatment. The cross-linking device includes a ring-shaped main body, a cylindrical channel part and a plano-convex lens. The main body has an annular shell body, the main body is made of opaque material, the channel part has a cylindrical shell, and one end of the cylindrical shell is connected to the outer wall of the annular shell, the plano-convex lens is arranged in the hollow area of ​​the annular shell, and the hollow area Form the treatment area during scleral treatment; the channel part integrates light guide lighting channel, drug delivery channel, negative pressure self-cleaning channel, and negative pressure fixed channel. The cross-linker and cross-linking system provided by the present invention propose a feasible plan for the cross-linking of posterior sclera collagen for the first time, which integrates drug delivery, negative pressure suction fixation, and self-cleaning functions while realizing lighting, creating an extremely With clinically applicable systemic equipment, ultraviolet A-riboflavin cross-linking technology can be applied to the posterior sclera, providing a new treatment method for the clinic.

Description

technical field [0001] The present invention generally relates to the technical field of ophthalmic disease treatment equipment, and in particular to a cross-linker and a cross-linking system for posterior sclera treatment. Background technique [0002] High myopia, also known as pathological myopia, is a common blinding eye disease. Retinal detachment, high myopia macular degeneration, retinal choroidal atrophy, posterior staphyloma, lacquer cracks, Fuch's spots and other pathological changes can occur, seriously impairing visual function . my country is one of the countries with the highest incidence of myopia in the world, and the incidence is as high as 70-90%. At the same time, the incidence of high myopia in my country is also very high. The survey of middle school students in western my country in 2015 showed that the prevalence of high myopia was ( 2.9±0.4)%, and middle school students over the age of 17 reached (9.9±3.0)%. Statistics on Shanghai college students in ...

AI Technical Summary

Problems solved by technology

[0007] For example, the prior Chinese patent CN104758119B discloses a riboflavin-ultraviolet sclera crosslinking method with a crosslinker. Its focus is only on light guide irradiation, without functions such as drug delivery. It has a clear focus and a single function.

[0008] Prior Chinese patents CN104936563B (device for medical treatment of sclera), CN106413644B (device for medical treatment of sclera) also all relate to the cross-linking equipment of certain structure, but its structural shape can not yet be very close to posterior sclera Well-matched, the size of the structure is large, it almost covers the entire posterior sclera during use, and cannot completely avoid the important structures of the posterior, but the actual anatomical structure suggests that there are many important structures of the posterior sclera, such as extraocular muscles, For important structures such as the optic nerve, at the same time, its treatment is not targeted, and it is not convenient to carry out drug delivery and irradiation therapy for a certain treatment area, and the design and layout of lighting, drug delivery, and drug recovery are not coordinated. The recovery effect is not good, and it cannot be operated according to the clinical operation steps. In particular, the patent does not have an automatic fixing structure and function. It cannot be automatically fixed on the scleral wall of the treatment area during use, and the product experience is poor.

Images